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Abstract: We developed a dextran-magnetite conjugated cisplatin (DM-Cis) complex for use in 
thermal ablation and as a chemotherapeutic drug. To produce DM-Cis we reacted Cis with 1 mL 
DM (56 mg/mL iron). The temperature rise of DM-Cis was measured in vitro and in vivo under 
a portable induction-heating (IH) device. Platinum desorption from DM-Cis over 24 hours was 
measured in bovine serum. In in vivo accumulation and magnet and exothermic experiments 
we used four rat groups. In group 1 we delivered DM-Cis intraperitoneally (ip) and placed 
magnets subcutaneously (sc). In group 2 we injected saline (ip) and placed magnets (sc). In 
group 3 we injected DM-Cis (ip) and placed a sc incision (sham). The control (group 4) received 
an ip injection of saline. Rectus abdominis muscle tissue was stained with hematoxylin-eosin 
and iron-stained tissue areas (µm2) were calculated. The maximum platinum concentration in 
DM-Cis was approximately 105.6 µg/mL. Over 24 hours, 33.48% of platinum from DM-Cis 
was released. There was a significant difference (P , 0.05) in the iron-stained area between 
group 1 and the other groups. The temperature in muscle tissue registered a maximum of 56°C 
after about 4 min. DM-Cis may represent a magnetically-accumulated anticancer drug with 
hyperthermic effects.
Keywords: magnetic nanoparticle-conjugated anticancer agents, DM, portable induction   heating 
device, carboxyl group, rat
Introduction
The purpose of this study was to develop a DM-Cis complex and to examine the 
  possibility of using DM-Cis for hyperthermic treatment and chemotherapy.
Magnetic nanoparticles have been used to diagnose tumors in the liver and spleen 
by magnetic resonance imaging (MRI).1 The in vivo accumulation of these particles 
in specific areas has been studied and the feasibility of hyperthermic treatment with 
magnetic particles has been investigated.2–10 As magnetic nanoparticles convert 
energy absorbed from an alternating magnetic field into heat, they may be useful for 
the delivery of hyperthermic therapy. Murata et al11 reported that anticancer agents 
delivered intraductally via the nipple may facilitate the administration of neoadjuvant 
therapy in patients with early breast cancer. We hypothesized that the availability of 
magnetic nanoparticle-conjugated anticancer agents may make it possible to treat 
various breast cancers by their intraductal administration and that this treatment would 
elicit hyperthermic effects.
DM is used widely as a liver-specific contrast medium (Resovist®; Bayer Health 
Care Japan, Osaka, Japan) and its safety has been established.1,8 DM consists of 
carboxy-dextran, which covers the core and the iron-oxide particles of the core. 
Therefore, a carboxyl group originating from dextran is present on the particle surface. International Journal of Nanomedicine  2010:5 submit your manuscript | www.dovepress.com
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The possibility of conjugating DM with the carboxyl group 
of gelatin and Cis was raised and gelatin-conjugated Cis was 
found to release Cis slowly, thereby potentially maximizing 
its anti-tumor effects.12,13 (Figure 1).
Methods
Preparation of DM-cis
A 1:1 ratio was defined as 1 mL Cis (1.43 mg/mL Cis) 
  (Nippon Kayaku Co., Tokyo, Japan) to 1 mL DM (56 mg/mL 
iron) (Meito, Aichi, Japan). We reacted various amounts of 
Cis with 1 mL DM. Initially we titrated Cis slowly into DM 
and followed this procedure with 7-day incubation at 37°C. 
In subsequent experiments we dialyzed the solution in 10 L 
of ultrapure double-distilled water (UDDW), exchanging the 
water 10 times in 7 days; we employed cellulose dialysis tub-
ing (MWCO14000; Viskase Co. Inc., IL, USA) and removed 
residual unconjugated Cis. The platinum concentration of 
DM-Cis was measured on an AA-6800 atomic absorption 
spectrometer (Shimadzu, Kyoto, Japan). When DM was 
reacted with Cis at a 1:1 ratio, we determined the size of the 
DM-Cis complex based on dynamic light scattering (DLS; 
light wave length 514 nm, sample temperature 25°C; Auto-
sizer 4700, Malvern Instruments, Worcestershire, UK).
exothermic experiment under  
a magnetic field
A portable IH device (alternating current (AC), 142 KHz 
magnetic field, single-phase, AC 200 V , electric current 440 
Amp, power consumption 3.5 kW) was the magnetic field 
generator.7 After reacting 2.5 mL Cis with 2.5 mL DM, we 
introduced a polyurethane tube containing 5 mL DM-Cis into 
the 20-cm diameter IH coil, set the IH device at 142 KHz, 
and measured the temperature for 10 minutes by inserting 
a thermometer (FL-2000; Anritsu Meter, Tokyo, Japan) into 
the tube.
Desorption of platinum from DM-cis  
in bovine serum
DM-Cis (3 mL) in cellulose dialysis tubing was immersed in 
bovine serum (9 mL) and shaken reciprocally (72 strokes/min) 
at 37°C. At 30 min and 1, 3, 6, 12, and 24 hours we withdrew 
0.5-mL bovine serum samples and immediately replaced them 
with the same volume of fresh bovine serum. The platinum 
concentration in the samples was then measured on an AA-6800 
atomic absorption spectrometer (Shimadzu, Kyoto, Japan).
In vivo accumulation and magnet  
and exothermic experiments
All experimental protocols were approved by our animal 
experimentation committee and all experiments were con-
ducted in accord with the Animal Care Guidelines of Shiga 
University of Medical Science.
Production of the magnet-bearing rat model
Wistar rats (SLC, Tokyo, Japan) were housed for more than 
one week in solid-floor cages in a dedicated   pathogen-free 
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Figure 1 Illustration of a complex comprised of DM and conjugated cis. A carboxyl group originating from dextran exists partially on the particle surface. The conjugation 
of DM with the carboxyl group of cis may result in a slow release of cis, thereby potentially maximizing its anti-tumor effect.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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animal facility at the Research Center for Animal Life 
  Science of our institution. The bedding was highly absorbent, 
free of materials toxic to humans and animals, and unpalat-
able to the animals. We provided sufficient bedding to keep 
the animals dry and unsoiled by feces and urine, the bedding 
did not interfere with the animals’ drinking. All bedding was 
stored on pallets to avoid contact with the floor. The room 
temperature was controlled at 22°C ± 4. The relative humid-
ity was controlled at 40%−70%. The rats received a diet of 
commercially available pellets and water ad libitum.
The animals were anesthetized with an ip injection of 
pentobarbital (40 mg/kg, Dai Nippon Sumitomo Pharma Co. 
Ltd., Tokyo, Japan). In six randomly selected rats from groups 
1 and 2 (three rats/group) we placed a 1-cm sc incision to 
create a pocket in the right lower quadrant for neodymium 
magnets (0.3 Tesla, 1 × 1 × 0.5 cm, Niroku Seisakusho, Shiga, 
Japan). Another 6 rats from groups 3 and 4 (3 rats/group) 
served as the control; they received similar sc incisions but 
no magnets were placed (Table 1). After the operation, all rats 
were injected intramuscularly with enrofloxacin (2.5%, 1 mL; 
Baytril®, Bayer Healthcare Co. Ltd., Tokyo, Japan) once a day 
for three consecutive days. On the seventh postoperative day 
they were used for the therapy portion of our study.
DM-cis accumulation experiment  
after ip administration
Four days after the ip injection of 1 mL saline (groups 2 and 
4, 3 rats/group) or 1 mL DM-Cis (groups 1 and 3, three rats/
group) into the left upper quadrant (Table 1) all rats were 
sacrificed with pentobarbital (400 mg/kg, ip; Dai Nippon 
Sumitomo Pharma Co.). The magnets were removed, rectus 
abdominis muscle tissue just under the pocket was harvested, 
fixed in 10% buffered formalin for 24 hours, and embedded in 
paraffin. A 4-µm-thick slice of a sagittal section relative to the 
magnets was deparaffinized and stained with hematoxylin and 
eosin (H and E) and Berlin blue for the detection of iron. The 
iron-stained area (um2) was calculated using Image-Pro Plus 
(Media Cybernetics, MD, USA). We extracted blue-stained 
portions from the muscle tissues (threshold: red 0–110, 
green 0–250, blue 0–250), computed the blue-stained area in 
one view (X100), recorded the average of 5 view areas, and 
evaluated the area stained positively for iron. For statistical 
analysis we used Dr SPSS II for Windows (SPSS Japan Inc., 
Tokyo, Japan). Significant differences in the iron-stained 
areas among groups of rats were determined with Tukey’s 
HSD test. A P value of ,0.05 was considered to indicate a 
significant difference.
In vivo exothermic experiment
Four rats were injected ip with DM-Cis and magnets were 
placed sc (Table 1). After 24 hours the magnets were removed 
from the pockets and 18-gauge venula catheter needles were 
inserted into the rectus abdominis muscle tissue just under 
the pocket to fix the thermometer (FL-2000; Anritsu Meter, 
Tokyo, Japan) at the target site. One thermometer was used to 
monitor the temperature in the rectus abdominis muscle tissue 
just under the pocket and another, inserted into the rectum, to 
monitor the rectal temperature. These rats were placed into 
the IH coil for temperature measurements.
Results
Size of DM-cis
The diameter of the DM-Cis complex was 59.6 ± 0.4 nm 
(± mean standard deviation).
Platinum concentration in DM-cis
Defining 1 mL DM to 1 mL Cis as a ratio of 1:1, the con-
centration of platinum at 1.0:0.05, 1.0:0.1, 1.0:0.5, and 1:1 
(DM:Cis) was 11.66 ± 1.13, 17.54 ± 1.84, 80.83 ± 2.91, and 
105.60 ± 9.03 ug/mL, respectively (Figure 2).
In vitro exothermic experiment  
using a magnetic field
Under the portable IH device, the DM-Cis (5 mL, DM: 
Cis = 1:1 (v:v) solution could be heated at a rate of 0.12°C/
sec. The temperature rose to 60°C in approximately 5 min 
 ( Figure 3).
Table 1 Protocol of the DM-cis accumulation experiment
Groups Magneto flasking  
subcutaneously
Intraperitoneal  
injection of DM-Cis
1 (Magnet/ip) + +
2 (Magnet) + −
3 (ip) − +
4 (control) − −
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Figure 2 Conjugated concentration of platinum in the DM complex. Defining 1 mL 
DM to 1 ml cis as a 1:1 ratio, this graph shows the concentration of platinum at 
1.0:0.05, 1.0:0.1, 1.0:0.5, and 1:1 (DM:cis). The platinum concentration at the applied 
concentrations of platinum conjugated with DM was 11.66 ± 1.13, 17.54 ± 1.84, 
80.83 ± 2.91, and 105.60 ± 9.0 ug/mL, respectively.International Journal of Nanomedicine  2010:5 submit your manuscript | www.dovepress.com
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concentration and desorption  
of platinum from DM-cis  
in bovine serum
Approximately 0.58, 1.20, 4.42, 9.30, 16.42, and 33.48% of 
platinum in DM-Cis was released at 30 min and at 1, 3, 6, 
12, and 24 hours, respectively. The platinum concentration 
in the solution remaining in the dialysis tube was 65.32% of 
the total amount of platinum (Figure 4).
In vivo intraperitoneal accumulation
In group 1 we observed an extraordinary accumulation of 
DM-Cis in the peritoneum just under the magnet (Figure 5). 
There was no such accumulation in the other groups (data 
not shown). In addition, there was a significant difference 
between group 1 and the other groups with respect to the 
accumulation of DM-Cis in muscle tissues (Figure 6).
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Figure 3 The temperature of DM-cis under a portable Ih device. Under the Ih 
device, DM-cis (5 mL, DM:cis = 1:1) could be heated at a rate of 0.12°c/sec. The 
temperature was maintained at 60°c for 5 minutes.
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Figure 4 Time course of platinum release from DM-cis in bovine serum. Approximately 0.58, 1.20, 4.42, 9.30, 16.42, and 33.48% of platinum in DM-cis was released at 
30 minutes and at 1, 3, 6, 12, and 24 hours, respectively.
In vivo exothermic experiment
Figure 7 shows the individual temperature profiles in rectus 
abdominis muscle tissue just under the pocket and in rectal 
tissue. The temperature in muscle tissues was maintained at 
a maximum of 56°C after 4 minutes. The rectal temperature 
elevation was slight. No rats died from exposure to high heat 
or electromagnetic waves.
Discussion
We developed a DM-Cis complex that manifests hyperther-
mic effects and is manipulated magnetically in the abdominal 
cavity of rats and at elevated temperatures in vivo under the 
IH system.
The size of the DM-Cis complex was 59.6 ± 0.4 nm. 
As DM measures 55.7 nm, there was apparently no DM-Cis 
aggregation. While aggregates of this DM-Cis complex may 
not spread well in breast ducts, the size of the formed DM-Cis 
complex can be expected to remain stable.
When we reacted DM with Cis at a 1:1 ratio, the plati-
num concentration of DM-Cis (DM:Cis = 1:1) was 105.60 ± 
9.03 ug/mL, approximately 32% of the platinum concentration 
in a pharmaceutical Cis preparation (Randa®, Nippon Kayaku 
Co. Ltd, Tokyo, Japan). The Cis concentration in DM-Cis is 
relatively high, rendering it clinically useful. Under the IH 
device, the temperature of DM-Cis in vitro rose to 60°C or 
more in approximately 5 min. At that temperature there are 
obvious hyperthermic effects. However, to be useful, Cis must 
be released from the DM-Cis complex. We found that in the International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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course of 24 hours, approximately 30% of Cis was desorbed 
in bovine serum, suggesting that the continued presence of 
Cis enhances its anti-tumor effects. In addition, DM-Cis 
accumulated in the rat peritoneum in a 0.3 Tesla magnetic 
field and as in muscle tissues just under the DM-Cis area, the 
iron concentration was clearly increased. It may be possible 
to trap DM-Cis for prolonged periods with a magnet in ducts 
and main tumor areas. The maximum temperature was 56°C 
and the area of hyperthermia was concentrated just beneath 
the in vivo DM-Cis accumulation site. For thermal treatment, 
temperatures of approximately 42°C are   considered sufficient 
to induce anti-tumor effects.14 A temperature rise to 56°C may 
coagulate targeted tissues directly.15
In one rat the temperature rose to 40.7°C in the rectus 
abdominis muscle tissue located just under the pocket. This 
raises the concern that some infused DM-Cis may be acciden-
tally injected into sc tissue, resulting in a decrease in the total 
A
C
B
D
Figure 5 Accumulation of DM-cis in group 1 rats. a) Macroscopic image of DM-cis accumulation in the peritoneum. b) h & e stains (X100) of rectus abdominis muscle 
tissue just under the pocket harboring the magnets. Note the aggregation of phagocytes in muscle tissue. c) Berlin-blue stains (X100). Iron distributed in the muscle tissues 
is blue. d) Masked image using Image-Pro Plus. Only portions dyed blue are identified by white dots using Image-Pro Plus.
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Figure 6 Total iron-stained area (µm2). Group 1 differed significantly from the other 
three groups with respect to the iron-stained area in muscle tissues (P , 0.05*,**,***). 
There was no significant difference among groups 2, 3, and 4.
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Figure 7 Temperature profiles of muscle and rectal tissues under the portable IH 
device. group 1 rats (n = 4) were placed into the Ih coil and the temperature was 
increased to 46.98 ± 7.0°c on average. The temperature in muscle tissues reached a 
maximum of 56°c after 4 min. The temperature increase in rectal tissue was slight. 
None of the experimental rats died from exposure to high heat or electromagnetic 
waves.International Journal of Nanomedicine
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amount of DM-Cis accumulated in the peritoneum and a low-
ering of the heat value. In another three rats, the temperature 
rise was sufficient to achieve hyperthermic effects. Moreover, 
these temperature gains were produced within 5 minutes, but 
according to others,6,7 the time required for similar tempera-
ture increases was longer. Our technique makes it possible to 
avoid raising the temperature in other parts of the body. None 
of our rats died during the heating procedure, suggesting the 
clinical applicability of this technique. Slow-release antitumor 
drugs with hyperthermic potential that can be magnetically 
manipulated and collected may be a more effective treatment 
of some cancers than surgical resection.
Our study has some limitations. Firstly, we did not 
compare the anti-tumor effects of DM-Cis in vivo and 
in vitro. Although Cis-conjugated gelatin maintained its 
anti-tumor effects in vivo,13 we need to determine whether 
Cis-  conjugated DM also retains these effects. Studies 
are underway in our laboratory to examine its effects in 
experimental mouse breast carcinoma. Secondly, we did 
not carry out ductal accumulation experiments. As ductal 
is slower than blood vessel flow, we posit that DM-Cis 
may fully accumulate magnetically. We are testing this 
hypothesis in a murine breast carcinoma model in which 
we administer DM-Cis via mammary ducts. Thirdly, we 
did not quantify the relationship between the concentra-
tion of accumulated iron and the distance between the site 
of accumulation and the site of temperature elevation. 
Our purpose in the current study was to examine whether 
DM-Cis can generate heat in vivo to the degree at which 
hyperthermia is induced. Fourthly, the long-term safety 
of DM-Cis remains to be established. However, as both 
DM and Cis are used clinically, these materials have been 
shown to be safe. We will perform additional experiments 
to address this issue. And finally, our study sample was 
deliberately small because our experiments to determine 
whether DM-Cis can generate heat in vivo exposed the 
animals to significant distress.
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